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Chromium (Cr) is a ubiquitous metal 
found in animals, plants, rocks, soil, and air 
(Hill et al. 2008). Exposure to hexa  valent 
chromium [Cr(VI)] occurs in multiple 
occupational environments, and the approxi­
mate daily absorbed dose of Cr(VI) is 
83–1,700 μg/kg/day (Beveridge 2010). The 
International Agency for Research on Cancer 
(1980) has classified Cr(VI) as a known 
human carcinogen. Previous in vivo studies 
strongly indicated that there is an association 
between Cr(VI) exposure and airway inflam­
mation and lung carcino  genesis (Beaver et al. 
2009a, 2009b; Zeidler­Erdely et al. 2008). 
However, the molecular mechanisms by 
which Cr(VI) induces lung inflammation and 
cancers are not yet well understood.
Prostaglandin (PG) is an important 
mediator at all stages of cancer development 
(Menter 2002). Cyclooxygenase (COX) is the 
rate­limiting enzyme in the synthesis of PGs 
(Rao et al. 2004). The COX enzyme system 
is composed of two isoenzymes: COX­1, the 
constitutive isoform, and COX­2, the induc­
ible protein (Davies et al. 2002). COX­2 can 
undergo rapid induction in response to many 
factors, such as growth factors and cytokines 
(Kirschenbaum et al. 2001), and is highly 
expressed in a variety of human cancers and 
cancer cell lines (Liao and Milas 2004). 
COX­2 over  expression is associated with 
more aggressive biological tumor behaviors 
(Liao and Milas 2004), and the inhibition 
of COX­2 has been regarded as an effective 
anti  cancer strategy (Davies et al. 2002). Thus, 
identification of the potential involvement of 
COX­2 and molecular mecha  nisms respon­
sible for COX­2 induction due to Cr(VI) 
exposure will provide significant insight 
into understanding Cr(VI) lung inflamma­
tory and carcino  genic effects. In the present 
study, we investigated the potential effects of 
Cr(VI) on COX­2 expression and molecular 
mechanisms leading to this induction in cell 
culture models.
Materials and Methods
Cell culture and reagents. Mouse embryonic 
fibro  blasts (MEFs) were cultured in 37°C 
with 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS),1% penicillin/
streptomycin, and 2 mM l­glutamine (all 
from Life Technologies, Grand Island, NY, 
USA) (Song et al. 2008). Normal human 
bronchial epithelial cells (NHBECs) were 
cultured in a modified LHC­9 medium 
(BioWhittaker, Inc., Walkersville, MD, USA) 
supplemented with 52 μg/mL bovine pituitary 
extract, 0.5 μg/mL hydrocortisone, 0.5 ng/mL 
human epidermal growth factor, 0.5 μg/mL 
epinephrine, 10 μg/mL transferrin, 5 μg/mL 
insulin, 0.1 ng/mL retinoic acid, 6.5 ng/mL 
triiodo  thyronine, 50 μg/mL gentamicin, and 
50 ng/mL amphotericin­B. We purchased 
antibodies specific for IκBα [inhibitor of 
transcription factor NFκB­α), phosphorylated 
IκBα (P­IκBα), c­Jun, phosphorylated c­Jun 
(P­c­Jun73), and IκB kinase β (IKKβ) from 
Cell Signaling Technology (Beverly, MA, 
USA); Antibodies against COX­2, Jun­B, 
Jun­D, c­Fos, Fra­1, and p65 from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA); 
anti­β­actin antibody from Sigma (St. Louis, 
MO, USA) and Sungene Biotech (Tianjin, 
China); and anti­p50 antibody from Abcam 
(Cambridge, MA, USA). The luciferase 
assay substrate was purchased from Promega 
(Madison, WI, USA), and sodium chromate 
(Na2CrO4) was purchased from Aldrich 
(Milwaukee, WI, USA).
Plasmid constructs and transfection. 
We purchased AP­1–luciferase (AP­1­Luc) 
plasmid from Stratagene (Santa Clara, CA, 
USA). The COX­2­Luc reporter plasmid, 
nuclear factor of activated T cells (NFAT)­
Luc reporter plasmid, nuclear factor κB 
(NFκB)­Luc reporter plasmid, dominant­
negative mutant of IKKβ (IKKβ­KM), 
hemagglutinin­tagged IKKβ (HA­IKKβ), and 
c­Jun dominant­negative mutant (pcDNA3.1/
His­TAM67), as well as IKKβ-/- and IKKα-/- 
MEFs and their corresponding wild­type 
(WT) MEFs, were described previously (Ding 
et al. 2006b; Ouyang et al. 2007a; Tang 
et al. 2001). Transfection experiments were 
performed with Lipofectamine 2000 reagent 
(Invitrogen, Carlsbad, CA, USA) following 
the manufacturer’s instructions. The stable 
transfectants were established and cultured 
in antibiotic­free DMEM for at least two 
passages before performing experiments.
Reverse-transcription polymerase chain 
reaction (RT-PCR). After the cells were treated 
with Na2CrO4, total RNA was extracted 
using TRIZOL reagent (Invitrogen) following 
the manufacturer’s instructions. First­strand 
cDNA was synthesized with oligo(dT)20 
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Ba c k g r o u n d: Hexavalent chromium [Cr(VI)] is recognized as a human carcinogen via inhalation. 
However, the molecular mechanisms by which Cr(VI) causes cancers are not well understood.
oBjectives: We evaluated cyclooxygenase-2 (COX-2) expression and the signaling pathway leading 
to this induction due to Cr(VI) exposure in cultured cells.
Me t h o d s : We used the luciferase reporter assay and Western blotting to determine COX-2 induc-
tion by Cr(VI). We used dominant negative mutant, genetic knockout, gene knockdown, and 
chromatin immuno  precipitation approaches to elucidate the signaling pathway leading to COX-2 
induction.
re s u l t s: We found that Cr(VI) exposure induced COX-2 expression in both normal human 
bronchial epithelial cells and mouse embryonic fibroblasts in a concentration- and time-dependent 
manner. Deletion of IKKβ [inhibitor of transcription factor NFκB (IκB) kinase β; an upstream 
kinase responsible for nuclear factor κB (NFκB) activation] or over  expression of TAM67 (a 
dominant-negative mutant of c-Jun) dramatically inhibited the COX-2 induction due to Cr(VI), 
suggesting that both NFκB and c-Jun/AP-1 pathways were required for Cr(VI)-induced COX-2 
expression. Our results show that p65 and c-Jun are two major components involved in NFκB 
and AP-1 activation, respectively. Moreover, our studies suggest crosstalk between NFκB and   
c-Jun/AP-1 pathways in cellular response to Cr(VI) exposure for COX-2 induction.
co n c l u s i o n: We demonstrate for the first time that Cr(VI) is able to induce COX-2 expression 
via an NFκB/c-Jun/AP-1–dependent pathway. Our results provide novel insight into the molecu  lar 
mechanisms linking Cr(VI) exposure to lung inflammation and carcinogenesis.
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primers using the SuperScript III First­Strand 
Synthesis System for RT­PCR; Invitrogen), 
and 1 μg of total RNA was used to perform 
reverse transcription. Specific primer pairs 
were designed for amplifying murine cox-2 
(forward, 5´­tca ccc gag gac tcc gcc­3´; reverse, 
5´­tcc tgc ccc aca gca aac tgc­3´) and β­actin 
(forward, 5´­gac gat gat att gcc gca ct­3´; 
reverse, 5´­gat acc acg ctt gct ctg ag­3´). For 
specific amplifications, 50 ng of cDNA tem­
plates was used. 
Luciferase reporter assay. MEFs trans­
fected with the luciferase reporter constructs 
were seeded into 96­well plates (8 × 103/well) 
and subjected to various treatments when cul­
tures reached 80–90% confluence. For ultra­
violet B (UVB) radiation, culture plates were 
covered with a thin layer of fresh medium 
(0.1% FBS­DMEM) and exposed to UVB 
light for 1 min, corresponding to a dose of 
1 kJ/m2, as reported previously (Song et al. 
2007). The UVB light source (UVP Inc., 
Upland, CA, USA) emitted > 95% 302­nm 
UVB light. Luciferase activity was determined 
using a luminometer (Wallac 1420 Victor 2 
multi  label counter system; PerkinElmer, 
Waltham, MA, USA) as described previously 
(Huang et al. 2002). The results are expressed 
as relative activity normalized to the luciferase 
activity in the control cells without treatment.
Western blotting assay. Cells (2 × 105) were 
seeded and cultured in each well of six­well 
plates until 70–80% confluence. The cells were 
exposed to Cr(VI) at varying doses and time 
points and then extracted with sodium dodecyl 
sulfate sample buffer as previously described 
(Ouyang et al. 2007b). The cell extracts were 
used for Western blotting with specific anti­
bodies. The protein band, specifically bound 
to the primary antibody, was detected using 
an anti­rabbit IgG­alkaline phosphatase 
(AP)–linked antibody and an electro  chemi­
fluorescence (ECF) Western blotting system 
(Amersham Biosciences, Piscataway, NJ, USA). 
The images were obtained by scanning using 
the Storm 860 phospho  imager (Molecular 
Dynamics, Sunnyvale, CA, USA) 
Electrophoretic mobility shift assay 
(EMSA) and super gel shift. We performed the 
EMSA using the LightShift Chemiluminescent 
EMSA Kit (Pierce, Rockford, IL, USA) 
according to the manufacturer’s instructions. 
Nuclear extracts were isolated with a Nuclear/
Cytosol Fractionation Kit (BioVision, 
Mountain View, CA, USA). The specific 
probe pair designed for activated NFκB 
was 5´­agt tga ggg gac ttt ccc agg c­3´ and 
5´­gcc tgg gaa agt ccc ctc aac t­3´. The specific 
probe pair designed for activated AP­1 was 
5´­cgc ttg atg agt cag ccg gaa­3´ and 5´­ttc 
cgg ctg act cat caa gcg­3´. The probes were 
conjugated with biotin by a Biotin 3´ End 
DNA Labeling Kit (Pierce) following the 
manufacturer’s instructions. Nuclear protein 
(4 μg) was subjected to the gel shift assay 
by incubation with 1 μg poly(dI­dC) DNA 
carrier in DNA binding buffer [10 mM 
Tris (pH 8.0), 150 mM potassium chloride, 
2 mM EDTA, 10 mM magnesium chloride, 
10 mM dithiothreitol, 0.1% bovine serum 
albumin, 20% glycerol]. The biotin­labeled 
double­stranded oligo  nucleo  tide (1 μL) was 
then added, and the reaction mixture was 
incubated at room temperature for 50 min. 
For competition experiments, a 50­fold molar 
Figure 1. Cr(VI) exposure resulted in COX-2 induction. WT MEFs (A,B) or NHBECs (C,D) were exposed to Cr(VI) as indicated. The cells were extracted and COX-2 
expression was determined by Western blotting (A,C,D) or by RT-PCR (B). β-Actin was used as a loading control. (E) WT MEFs were treated with Cr(VI) at indi-
cated doses for 6 and 12 hr and then allowed to recover in normal culture medium for 24 hr; cytotoxicity was determined by colony survival assay. (F,G) COX-2 
promoter–driven luciferase transcription relative to control (relative COX-2 transcription) was determined in MEFs treated with 20 μM Cr(VI) for various times (F) 
or at different Cr(VI) doses for 12 hr (F). Data are mean ± SD of triplicates.
*p < 0.05, compared with control cells (medium only).
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excess of the unlabeled double­stranded oligo­
nucleo  tide was added before the addition of 
the labeled probe. For the super gel shift assay, 
nuclear extracts were incubated with 2 μg 
antibody for 30 min at 4°C before addition 
of the probe. DNA–protein complexes were 
resolved by electrophoresis on 5% non­
denaturing glycerol­polyacrylamide gels. 
The luminescent signal was developed by a 
LightShift® Chemiluminescent EMSA Kit and 
detected by an automatic developing machine. 
Chromatin immunoprecipitation (ChIP) 
assay. The ChIP assay was performed using the 
EZ ChIP kit (Upstate, Billerica, MA, USA) 
according to the manufacturer’s instructions. 
Briefly, cells were either untreated or treated 
with Cr (20 μM) for 12 hr, and then genomic 
DNA and the proteins were cross­linked with 
1% formaldehyde. The cross­linked cells were 
pelleted, resuspended in lysis buffer, and soni­
cated to generate 200­ to 500­bp chroma­
tin DNA fragments. After centrifugation, the 
supernatants were diluted 10­fold and then 
incubated with anti­p65 or anti­c­Jun anti­
bodies, respectively, or the control rabbit IgG 
at 4°C over  night. The immune complex was 
captured by protein G agarose saturated with 
salmon sperm DNA and then eluted with elu­
tion buffer. DNA–protein cross­linking was 
reversed by heating at 65°C for 4 hr. DNA 
was purified and subjected to PCR analysis. 
To specifically amplify the region con­
taining the putative NFκB­responsive ele­
ments on the mouse COX-2 promoter, we 
performed PCR using the following prim­
ers: 5´­ctg acg agc gag cac gtc­3´ (forward) 
and 5´­ttt ggc ctc tgg ggt ttc­3´ (reverse). To 
specifically amplify the region containing 
the putative AP­1–responsive elements on 
the mouse COX-2 promoter, PCR was per­
formed with the following primers: 5´­ttc cca 
taa gac tcc g­3´ (forward) and 5´­gct tca tgt 
gca agc t­3´ (reverse). Primers targeting the 
region 1 kb upstream of the NFκB and AP­1 
binding sites on the COX-2 promoter were 
also used in the PCR analysis to support the 
specificity of the ChIP assay: 5´­tga ttt ggt ttg 
gga ca­3´ (forward) and 5´­ctg gag gac aag agc 
agt­3´ (reverse).
Clonogenic survival assay. MEFs were 
treated with Cr(VI) at 5 μM and 20 μM for 
6 and 12 hr and recovered for 24 hr in nor­
mal culture medium. Cells were then plated 
at 500 cells/dish in 100­mm cell culture 
dishes and cultured for 2 weeks. Cells were 
stained with Giemsa solution, and the num­
ber of colonies was counted and presented as 
mean ± SD (n = 3).
Statistical analysis. We used the Student’s 
t­test to determine the significance of differ­
ence in COX­2 induction and AP­1, NFAT, 
or NFκB activation in luciferase reporter 
assays among various groups. The statistical 
significance level was set at p < 0.05.
Results
Cr(VI) exposure induced COX-2 expression. 
As shown in Figure 1A, treatment of MEFs 
with Cr(VI) resulted in an increase in 
COX­2 protein expression in a dose­ and 
time­dependent manner. We observed 
marked induction at 12 hr and 24 hr after 
exposure. Cr(VI) exposure was previously 
reported to induce either cell growth arrest 
and/or apoptosis in a dose­, time­ and, cell­
type–dependent manner (Wang et al. 2004). 
To evaluate the cyto  toxicity of Cr(VI) in our 
experimental system, we subjected Cr(VI)­
treated MEFs to a colony­survival assay. 
Results showed only marginal toxicity on 
MEFs exposed to 20 μM Cr(VI) after 12 hr 
of exposure, whereas there was no observable 
cyto  toxicity at 5 μM (Figure 1E). These 
results are consisted with a previous report 
showing that the viability of HaCaT (human 
keratino  cyte) cells is not affected at Cr(VI) 
concentrations as high as 30 μM (Wang et al. 
2010). Consistent with protein induction, 
marked induction of COX-2 mRNA by 
20 μM Cr(VI) was present as early as 6 hr 
after exposure, suggesting that Cr(VI) might 
induce COX-2 expression at a transcriptional 
level (Figure 1B). To test this notion, we 
investigated the effects of Cr(VI) on COX-2 
promoter activity in the stable transfectant of 
COX-2 promoter–driven luciferase reporter. 
As shown in Figure 1F and 1G, treatment 
with Cr(VI) resulted in a marked increase in 
COX-2 promoter activity. This induction was 
also observed with 20 μM Cr(VI) as early as 
at 6 hr after exposure (Figure 1F), which is 
consistent with the results of the RT­PCR 
assay. The respiratory tract is the primary 
target organ of Cr(VI) (Goldoni et al. 2008). 
Thus, we used NHBECs to test the effect of 
Cr(VI) on COX­2 expression. Cr(VI) exposure 
did cause COX­2 expression in NHBECs 
(Figure 1C,D). Collectively, these results 
indicate that Cr(VI) is able to induce COX­2 
expression in both MEFs and NHBECs.
Cr(VI) exposure induced the activation 
of NFκB and AP-1 but not NFAT. Cr(VI) 
treatment did not result in observable NFAT 
activation (Figure 2A), whereas UVB expo­
sure, the positive control, resulted in signifi­
cant NFAT activation (Figure 2B) in the 
same stable NFAT­Luc reporter transfectant. 
Figure 2. Cr(VI) treatment induced the activation of NFκB and AP-1 but not NFAT. (A–D) NFAT-
dependent (A and B), NFκB-dependent (C), and AP-1–dependent (D) transactivation in MEFs was deter-
mined by specific luciferase reporter assay after exposure to different concentrations of Cr(VI) for 12 hr 
or UVB (1 kJ/m2) for 6 hr. Values are mean ± SD of triplicates. (E) MEFs were exposed to Cr(VI) for 1 hr 
and then extracted and subjected to Western blotting analysis. β-Actin was used as a loading control. 
(F,G) MEFs were exposed to 20 μM Cr(VI), and the nuclear extracts were subjected to the gel shift assay 
with NFκB (F) or AP-1 (G) probe. For competition experiments, a 50-fold molar excess of unlabeled NFκB 
or AP-1 cold probe was added to the binding reaction mixtures to determine the specific binding. 
*p < 0.05, compared with control. 
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In contrast to NFAT, NFκB activation was 
signifi  cantly increased by Cr(VI) treatment in 
the NFκB­Luc reporter assay (Figure 2C). The 
activation of the NFκB pathway by Cr(VI) was 
further verified by the observation of increased 
IκBα phosphoryla  tion and degradation in the 
Western blotting assay (Figure 2E) and NFκB 
DNA binding activity analyzed by an EMSA 
assay (Figure 2F). We further determined 
the involvement of the AP­1 pathway in cells 
exposed to Cr(VI). As shown in Figure 2D 
and 2G, treatment of cells with Cr(VI) for 
6 hr also led to marked AP­1 induction in the 
AP­1­Luc reporter assay (Figure 2D) and the 
AP­1 EMSA assay (Figure 2G). These results 
demonstrate that Cr(VI) exposure induced 
activation of NFκB and AP­1 but not NFAT. 
DNA binding activity of NFκB induced 
by Cr(VI) reached to peak at 3 hr (Figure 2F), 
whereas the maxi  mum AP-1 DNA binding 
activity was achieved at 9 hr after exposure 
(Figure 2G). The difference could be due 
to the differential pathways responsible 
for activation of NFκB and AP­1. NFκB 
activation is fully dependent on IKKβ/IκB 
phosphorylation/degradation (Song et al. 
2006), whereas AP­1 activation is dependent 
on both c­Jun phosphorylation and increased 
c­Jun protein expression (Huang et al. 1999a, 
1999b). The induction of c­Jun protein 
expression may lead to the delay of maximum 
AP­1 activation compared with the peak of 
NFκB activation. Cr(VI) has been reported 
to inhibit tumor necrosis factor­α–induced 
NFκB transcriptional competence through 
inhibiting inter  actions with coactivators 
of transcription rather than DNA binding 
(Shumilla et al. 1999). Another study found 
that Cr(VI) prevented the benzo[a]pyrene­
dependent release of histone deacetylase­1 
from cytochrome P450 1a1 chromatin and 
blocked p300 recruitment (Wei et al. 2004). 
IKKβ is required for CI(VI)-induced 
COX-2 expression. To clarify the potential role 
of IKKβ in Cr(VI)­induced COX­2 expres­
sion, we used IKKβ­KM, an inactive mutant 
of IKKβ, and IKKβ-/- MEFs. As shown in 
Figure 3A, over  expression of IKKβ­KM 
in MEFs inhibited Cr(VI)­induced COX­2 
expression in the COX­2­Luc reporter assay. 
The knockout of IKKβ (Figure 3B) impaired 
the phosphorylation and degradation of its 
downstream target IκBα after Cr(VI) treat­
ment (Figure 3C), indicating the necessary 
role of IKKβ in Cr(VI)­induced NFκB activa­
tion. Cr(VI)­induced COX­2 protein expres­
sion was consistently blocked in IKKβ-/- cells 
(Figure 3D). Moreover, reconstituted expres­
sion of IKKβ in IKKβ-/- cells restored COX­2 
induction (Figure 3E). Our results demonstrate 
that IKKβ was required for COX­2 induc­
tion after Cr(VI) exposure. Overexpression of 
IKKβ­KM was not able to completely inhibit 
COX-2 promoter–driven luciferase transcrip­
tion (Figure 3A), whereas IKKβ deletion 
(IKKβ-/-) was able to block COX­2 expression 
completely (Figure 3D). These results suggest 
that IKKβ­KM over  expression was not able to 
completely impair endogenous IKKβ function. 
The potential role of NFκB p65 in the 
regu  lation of COX-2 expression due to Cr(VI) 
exposure. NFκB components are expressed 
in a variety of cell types (Karin and Greten 
2005). In a previous study we showed that 
the NFκB p65 sub  unit, but not the p50 sub­
unit, is required for nickel­induced COX­2 
expression in Beas­2B cells (Ding et al. 2006b). 
In the present study, we determined the dif­
ferential involvement of p65 and p50 sub  units 
in Cr(VI)­induced COX­2 expression. We per­
formed a super gel shift assay in the presence 
of the anti  bodies specific for p65 or p50. As 
shown in Figure 3F, selective reduction of the 
p65 band was observed using anti­p65 anti­
body, whereas no reduction of DNA binding 
activity was observed with anti­p50 anti  body. 
Incubation of cell nucleus extracts with anti­
p65 antibody reduced the extract protein bind­
ing to the NFκB probe but did not cause the 
supershift band. The explanation for this may 
be that binding of anti­p65 antibody to p65 
protein changes the p65 protein conforma­
tion and in turn leads to p65 losing its bind­
ing activity to the NFκB probe. These results 
suggest that p65 might be the major compo­
nent involved in NFκB activation after Cr(VI) 
exposure. This notion is further supported 
by ChIP assay data. As shown in Figure 3G, 
Cr(VI) treatment markedly enhanced recruit­
ment of the p65 subunit to its binding site in 
COX-2 promoters, whereas control IgG and 
primers targeting the DNA sequence located 
at approximately 1 kb upstream of the NFκB 
binding site in the COX-2 promoter did not 
Figure 3. IKKβ/NFκB activation is required for Cr(VI)-induced COX-2 expression in MEFs. (A) MEFs were 
exposed to Cr(VI) for 6 hr, and the luciferase activities were determined; results are expressed as COX-2 
induction relative to control. (B) IKKβ expression in WT and IKKβ–/– MEFs. (C–E) WT (vector), IKKβ–/– 
(vector), and IKKβ–/– (IKKβ) MEFs were seeded into six-well plates, and Western blotting analysis was 
performed with anti–P-IκBα and anti-IκBα (C), anti-COX-2 (D), or anti-COX-2 and anti-IKKβ (E). β-Actin 
was used as a loading control. (F) MEFs were exposed to 20 μM Cr(VI) for 3 hr, and then the nuclear 
extracts were subjected to a super gel shift assay using anti-p65 and anti-p50. (G) MEFs were exposed to 
20 μM Cr(VI) for 3 hr, and then the ChIP assay was performed. 
*p < 0.05, compared with WT (vector) cells. 
8
6
4
2
0
WT(vector) IKKβ-KM
*
*
R
e
l
a
t
i
v
e
 
C
O
X
-
2
 
t
r
a
n
s
c
r
i
p
t
i
o
n
P-IκBa
IκBα
β-Actin
WT IKKβ–/–
20 5 0 20 5 0 Cr(VI) (µM)
COX-2
β-Actin
WT IKKβ–/–
20 5 0 20 5 0 Cr(VI) (µM)
COX-2
IKKβ
β-Actin
WT IKKβ–/– IKKβ–/– (IKKβ)
20 20 5 50 0 20 5 0 Cr(VI) (µM)
Input
–+ + + –
p65 IgG
NFκB ﬂanking region
Nonrelevant region
Cr(VI) (20 µM)
Complex
Free probes
–
–
+
–
–
+
Anti-p65
Anti-p50
Cr(VI) (20 µM)
NFκB probe
IKKβ
β-Actin
WT IKKβ–/–
Cr(VI) 0 µM
Cr(VI) 5 µM
Cr(VI) 20 µMHexavalent chromium-induced COX-2 overexpression
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 4 | April 2012  551
show detectable PCR products (Figure 3G). 
Taken together, these results demonstrate that 
NFκB p65, rather than the p50 subunit, plays 
a key role in NFκB activation and COX­2 
induction after Cr(VI) exposure.
Involvement of c-Jun/AP-1 in Cr(VI)-
induced COX-2 expression. Different AP­1 
dimers play different roles in the regulation of 
cellular function and carcino  genesis (Song et al. 
2008). Western blotting shows that Cr(VI) 
exposure resulted in c­Jun phosphorylation, 
but we observed no activation of other AP­1 
members Jun B, Jun D, c­Fos, or Fra­1 
(Figure 4A). To determine the role of c­Jun in 
Cr(VI)­induced AP­1 activation, we performed 
a super gel shift assay using antibodies specific 
for c­Jun and c­Fos. As shown in Figure 4B, we 
observed a selective supershift band of c­Jun in 
cell extracts from Cr(VI)­treated cells, but no 
c­Fos supershift band was observable, suggesting 
that c­Jun was the major component involved 
in AP­1 activation due to Cr(VI) exposure. 
COX-2 has been shown to be a typical AP­1–
regulated gene in several experimental systems 
(Zhang et al. 2010). Thus, we determined the 
recruitment of c­Jun to the COX-2 promoter 
region using the ChIP assay. The detection of 
the COX-2 promoter in the antibody­captured 
genomic DNA fragments was performed by 
PCR amplification with primers designed to 
specifically recognize the region containing 
AP­1–responsive elements. Anti­c­Jun antibody 
strongly coimmuno    precipitated the target 
COX-2 promoter region DNA in Cr(VI)­
treated cell extract but not in the control cell 
extract (Figure 4C), indicating the inducible 
recruitment of c­Jun to the endogenous 
COX-2 promoter after Cr(VI) exposure. This 
demonstrates Cr(VI)­inducible recruitment of 
AP­1 onto the endogenous COX-2 promoter 
region (Figure 4C), suggesting that AP­1 
might play a role in the regulation of COX­2 
expression due to Cr(VI) exposure. To test this 
notion, we used TAM67, a dominant negative 
mutant of c­Jun. The ectopic expression of 
TAM67 in WT cells attenuated Cr(VI)­induced 
c­Jun phosphorylation in MEFs (Figure 4E). 
Unlike over  expression of IKKβ­KM in 
MEFs (Figure 3A), COX-2 promoter–driven 
luciferase transcription was impaired in WT/
TAM67 transfectant (Figure 4D), suggesting 
that TAM67 over  expression was able to block 
the endogenous c­Jun function. COX­2 
protein induction by Cr(VI) was also blocked 
(Figure 4E). These results demonstrate 
that c­Jun activation is essential for COX­2 
induction after Cr(VI) exposure.
Crosstalk between AP-1 and NFκB 
pathways after Cr(VI) exposure. Crosstalk 
between AP­1 and NFκB has been reported 
to be responsible for the synergistic increase 
in their activity in the regulation of target 
gene expression (Adcock 1997). Thus, we 
determined the potential relation  ship of these 
two transcription factors in response to Cr(VI) 
exposure in cells. We used IKKβ-/- MEFs to 
examine whether the impairment of the NFκB 
pathway could affect c­Jun phosphoryla  tion. 
Impairment of the NFκB pathway inhibited 
c­Jun phosphorylation (Figure 5A), suggesting 
Figure 4. Requirement of c-Jun/AP-1 for Cr(VI)-induced COX-2 expression. (A) MEF cells were exposed 
to Cr(VI) for 12 hr, and cell extracts were subjected to Western blotting. (B) MEFs were exposed to 
20 μM Cr(VI) for 6 hr, and nuclear extracts were subjected to a super gel shift assay for c-Jun and c-Fos. 
(C) MEFs were exposed to 20 μM Cr(VI) for 3 hr, before performing the ChIP assay. (D) MEFs transiently 
transfected with the COX-2-Luc reporter construct or COX-2-Luc reporter together with a c-Jun mutant 
construct (TAM67) were then exposed to Cr(VI), and the luciferase activities were determined 6 hr after 
treatment. Results are expressed as COX-2 induction relative to control. (E) WT (vector) or TAM67 MEFs 
cells were treated with Cr(VI) for 24 hr, and cell extracts were subjected to Western blotting. β-Actin was 
used as a loading control. 
*p < 0.05, compared with WT (vector) MEFs. 
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that NFκB activation has a positive effect 
on c­Jun activation after Cr(VI) exposure. 
To further reveal the potential effects of 
c­Jun/AP­1 on NFκB activation, we used a 
dominant negative mutant of c­Jun (TAM67). 
As shown in Figure 5B, ectopic expression 
of TAM67 had an inhibitory effect on 
IκBα phosphorylation, suggesting that the 
phosphorylation of c­Jun was also involved in 
the regulation of the NFκB pathway. Taken 
together, the AP­1 and NFκB pathways did 
show crosstalk after Cr(VI) treatment, which 
might play a role in Cr(VI)­induced COX­2 
induction and carcinogenesis (Figure 5C).
Discussion
The data we present here indicate that Cr(VI) 
induced expression of COX­2 and activation 
of AP­1 and NFκB, and show that both AP­1 
and NFκB are required for Cr(VI)­induced 
COX­2 expression. Our data also indicate 
the presence of cross  talk between the NFκB 
and AP­1 pathways after Cr(VI) exposure, 
which mainly occurred via IKKβ/p65­ 
dependent and c­Jun–dependent pathways. 
Considering the important role of COX­2 in 
the mediation of chronic inflammation and 
lung carcino  genesis, we anticipated that acti­
vation of NFκB and AP­1 pathways and their 
crosstalk in the regulation of COX­2 expres­
sion might be key factors in Cr(VI)­induced 
lung carcino  genesis. Further elucidating the 
relationship among chronic inflammation, 
COX­2 induction, and lung carcinogenic 
effect after various doses of Cr(VI) exposure 
in vivo animal models will be a major focus 
for future investigations in our laboratory, 
which might help determine a threshold dose 
for lung carcinogenesis of Cr(VI) exposure.
Inflammation is implicated in Cr(VI)­
induced human lung cancer development. 
Repetitive exposure to Cr(VI) results in persis­
tent inflammation, and such an inflammatory 
micro  environment can further promote lung 
carcino  genesis (Beaver et al. 2009a, 2009b). 
COX­2 plays an important role in the develop­
ment of various types of cancer, including lung 
cancer (Sahin et al. 2009), and drugs targeting 
this enzyme have achieved widespread clinical 
use (Bertagnolli 2007). Our previous studies 
have shown that COX­2 induction is involved 
in several carcino  genic responses (Ding et al. 
2006a, 2006b; Li et al. 2006). In the pres­
ent study, we initially found that exposure to 
Cr(VI) induced COX­2 expression in both 
NHBECs and MEFs. Considering the critical 
role of COX­2 in the inflammatory processes 
of cancer and the importance of an inflamma­
tory micro  environment during carcino  genesis 
after Cr(VI) exposure, our results may shed 
light into the mechanisms of Cr(VI)­induced 
carcinogenic effects.
The COX-2 promoter region contains 
the binding sites of three major transcription 
factors: NFκB (Crofford et al. 1997), AP­1 
(Subbaramaiah et al. 2002), and NFAT 
(Iniguez et al. 2000). These three factors have 
been reported to be major mediators for the 
regulation of cell proliferation, differentia­
tion, and transformation (Huang et al. 1999a, 
1999b). In the present study, we observed 
that Cr(VI) exposure resulted in the activa­
tion of NFκB and AP­1, whereas there was 
no observable NFAT activation, which is 
consistent with published studies showing 
that Cr(VI) exposure leads to the activation 
of NFκB and AP­1 in an oxidative­stress–
dependent manner (Yao et al. 2008). NFκB 
activation has been reported to be involved 
in the development of several cancers (Biswas 
et al. 2004; Wang et al. 2003). Our published 
studies have shown that NFκB activation is 
involved in cellular responses to several envi­
ronmental carcinogens (Ding et al. 2007; 
Ouyang et al. 2007b). In the present study, 
we found that IKKβ was critical for Cr(VI)­
induced NFκB activation and COX­2 expres­
sion. In addition, we showed that p65, rather 
than p50, was required for Cr(VI)­induced 
NFκB activation and COX­2 expression. We 
observed that Cr(VI) exposure induces NFκB 
activation via an IKKβ/p65­dependent path­
way, which further leads to COX­2 induc­
tion. Cr(VI) increases formation of reactive 
oxygen species (ROS) in certain cell types 
(Wang et al. 2010), and the inductive COX­2 
expression of manganese is accompanied by 
generation of oxidative stress and increased 
NFκB and AP­1 DNA binding activities 
(Chen et al. 2007). Thus, we anticipate that 
ROS generation may also be involved in the 
activation of NFκB and AP­1, which further 
leads to COX­2 expression.
The c­Jun/AP­1 pathway is crucial for 
COX­2 induction caused by some environ­
mental stresses (Ouyang et al. 2007a; 
Zhang et al. 2008). Because of the multiple 
functions of AP­1 proteins, the selection of 
the different AP­1 dimers is considered as 
another mechanism for the modulation 
of AP­1 activity (Song et al. 2008). The 
results of the present study indicate that 
AP­1 activation due to Cr(VI) exposure 
mainly involves c­Jun phosphorylation. The 
predominant role of c­Jun in Cr(VI)­induced 
AP­1 transactivation and COX­2 induction 
was further confirmed by super gel shift assay 
and ChIP assay. Furthermore, transfection 
with the dominant negative c­Jun mutant 
(TAM67) blocked Cr(VI)­induced COX­2 
expression. In addition, the knockout of 
IKKβ impaired Cr(VI)­induced c­Jun 
phosphorylation, whereas inhibition of the 
c­Jun/AP­1 pathway by over  expression of 
TAM67 also inhibited Cr(VI)­induced IκBα 
phosphorylation, suggesting crosstalk between 
the c­Jun/AP­1 pathway and the IKKβ/NFκB 
pathway in the Cr(VI) response. Because both 
the c­Jun/AP­1 pathway and the IKKβ/NFκB 
pathway are crucial for COX­2 induction, we 
anticipate that this crosstalk may play a key 
role in Cr(VI)­induced COX­2 expression, 
which provides a novel model of the inter­
action between NFκB and AP­1 pathways 
for environmental responses. Considering 
that inhibition of NFκB, AP­1, and COX­2 
has been proposed as potential anti  cancer 
strategies, our results may lead to new targets 
for chemo  prevention of Cr(VI)­induced 
human carcinogenesis.
RefeRences
Adcock IM. 1997. Transcription factors as activators of gene 
transcription: AP-1 and NF-kappa B. Monaldi Arch Chest 
Dis 52(2):178–186.
Beaver LM, Stemmy EJ, Constant SL, Schwartz A, Little LG, 
Gigley JP, et al. 2009a. Lung injury, inflammation and Akt 
signaling following inhalation of particulate hexa  valent 
chromium. Toxicol Appl Pharmacol 235(1):47–56.
Beaver  LM,  Stemmy  EJ,  Schwartz  AM,  Damsker  JM, 
Constant SL, Ceryak SM, et al. 2009b. Lung inflammation, 
injury, and proliferative response after repetitive particulate 
hexavalent chromium exposure. Environ Health Perspect 
117:1896–1902.
Bertagnolli MM. 2007. Chemoprevention of colorectal cancer 
with cyclooxygenase-2 inhibitors: two steps forward, one 
step back. Lancet Oncol 8(5):439–443.
Beveridge R, Pintos J, Parent ME, Asselin J, Siemiatycki J. 
2010. Lung cancer risk associated with occupational 
exposure to nickel, chromium VI, and cadmium in two 
population-based case-control studies in Montreal. Am J 
Ind Med 53(5):476–485. 
Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, 
et al. 2004. NF-κB activation in human breast cancer spec-
imens and its role in cell proliferation and apoptosis. Proc 
Natl Acad Sci USA 101(27):10137–10142.
Chen CJ, Liao SL, Ou YC, Chen SY, Chiang AN. 2007. Induction 
of cyclooxygenase-2 expression by manganese in cultured 
astrocytes. Neurochem Int 50(7–8):905–915.
Crofford LJ, Tan B, McCarthy CJ, Hla T. 1997. Involvement of 
nuclear factor kappa B in the regulation of cyclo  oxygenase-2 
expression by interleukin-1 in rheumatoid synoviocytes. 
Arthritis Rheum 40(2):226–236.
Davies G, Martin LA, Sacks N, Dowsett M. 2002. Cyclooxygenase-2 
(COX-2), aromatase and breast cancer: a possible role for 
COX-2 inhibitors in breast cancer chemoprevention. Ann 
Oncol 13(5):669–678.
Ding J, Li J, Xue C, Wu K, Ouyang W, Zhang D, et al. 2006a. 
Cyclooxygenase-2 induction by arsenite is through a 
nuclear factor of activated T-cell-dependent pathway and 
plays an anti  apoptotic role in Beas-2B cells. J Biol Chem 
281(34):24405–24413.
Ding J, Wu K, Zhang D, Luo W, Li J, Ouyang W, et al. 2007. 
Activation of both nuclear factor of activated T cells and 
inhibitor of nuclear factor-κB kinase β-subunit-/nuclear 
factor-κB is critical for cyclo  oxygenase-2 induction by 
benzo[a]pyrene in human bronchial epithelial cells. Cancer 
Sci 98(9):1323–1329.
Ding J, Zhang X, Li J, Song L, Ouyang W, Zhang D, et al. 
2006b. Nickel compounds render anti-apoptotic effect to 
human bronchial epithelial Beas-2B cells by induction 
of cyclooxygenase-2 through an IKKβ/p65-dependent 
and IKKα- and p50-independent pathway. J Biol Chem 
281(51):39022–39032.
Goldoni M, Caglieri A, Corradi M, Poli D, Rusca M, Carbognani P, 
et al. 2008. Chromium in exhaled breath condensate and 
pulmonary tissue of non-small cell lung cancer patients. Int 
Arch Occup Environ Health 81(4):487–493.
Hill R, Leidal AM, Madureira PA, Gillis LD, Cochrane HK, 
Waisman DM, et al. 2008. Hypersensitivity to chromium-
induced DNA damage correlates with constitutive 
deregulation of upstream p53 kinases in p21-/- HCT116 
colon cancer cells. DNA Repair (Amst) 7(2):239–252.
Huang C, Huang Y, Li J, Hu W, Aziz R, Tang MS, et al. 2002. 
Inhibition of benzo(a)pyrene diol-epoxide-induced trans-
activa  tion of activated protein 1 and nuclear factor κB by 
black raspberry extracts. Cancer Res 62(23):6857–6863.Hexavalent chromium-induced COX-2 overexpression
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 4 | April 2012  553
Huang C, Ma WY, Dong Z. 1999a. The extracellular-signal-
regulated protein kinases (Erks) are required for UV-induced 
AP-1 activation in JB6 cells. Oncogene 18(18):2828–2835.
Huang C, Ma WY, Li J, Goranson A, Dong Z. 1999b. Requirement 
of Erk, but not JNK, for arsenite-induced cell transforma-
tion. J Biol Chem 274(21):14595–14601.
Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, 
Fresno M. 2000. An essential role of the nuclear factor of 
activated T cells in the regulation of the expression of the 
cyclooxygenase-2 gene in human T lymphocytes. J Biol 
Chem 275(31):23627–23635.
International Agency for Research on Cancer. 1980. Some Metals 
and Metallic Compounds. IARC Monogr Eval Carcinog Risk 
Chem Hum 23:1–415.
Karin M, Greten FR. 2005. NF-κB: linking inflammation and 
immunity to cancer development and progression. Nat Rev 
Immunol 5(10):749–759.
Kirschenbaum A, Liu X, Yao S, Levine AC. 2001. The role of 
cyclooxygenase-2 in prostate cancer. Urology 58(2 suppl 
1):127–131.
Li J, Song L, Zhang D, Wei L, Huang C. 2006. Knockdown of 
NFAT3 blocked TPA-induced COX-2 and iNOS expression, 
and enhanced cell transformation in Cl41 cells. J Cell 
Biochem 99(4):1010–1020.
Liao Z, Milas L. 2004. COX-2 and its inhibition as a molecular 
target in the prevention and treatment of lung cancer. 
Expert Rev Anticancer Ther 4(4):543–560.
Menter DG. 2002. Cyclooxygenase 2 selective inhibitors in cancer 
treatment and prevention. Expert Opin Investig Drugs 
11(12):1749–1764.
Ouyang W, Ma Q, Li J, Zhang D, Ding J, Huang Y, et al. 2007a. 
Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 
expression through MAPKs/AP-1 and IKKβ/NF-κB in 
mouse epidermal Cl41 cells. Mol Carcinog 46(1):32–41.
Ouyang W, Zhang D, Ma Q, Li J, Huang C. 2007b. Cyclo-
oxygenase-2 induction by arsenite through the IKKβ/NFκB 
pathway exerts an antiapoptotic effect in mouse epidermal 
Cl41 cells. Environ Health Perspect 115:513–518.
Rao M, Yang W, Seifalian AM, Winslet MC. 2004. Role of 
cyclooxygenase-2 in the angiogenesis of colorectal cancer. 
Int J Colorectal Dis 19(1):1–11.
Sahin M, Sahin E, Gumuslu S. 2009. Cyclooxygenase-2 in cancer 
and angiogenesis. Angiology 60(2):242–253.
Shumilla JA, Broderick RJ, Wang Y, Barchowsky A. 1999. 
Chromium(VI) inhibits the transcriptional activity of nuclear 
factor-κB by decreasing the interaction of p65 with cAMP-
responsive element-binding protein-binding protein. J Biol 
Chem 274(51):36207–36212.
Song L, Li J, Hu M, Huang C. 2008. Both IKKα and IKKβ are 
implicated in the arsenite-induced AP-1 transactivation 
correlating with cell apoptosis through NF-κB activity-
independent manner. Exp Cell Res 314(11–12):2187–2198.
Song L, Li J, Ye J, Yu G, Ding J, Zhang D, et al. 2007. p85 
acts as a novel signal transducer for mediation of cellu-
lar apoptotic response to UV radiation. Mol Cell Biol 
27(7):2713–2731.
Song L, Li J, Zhang D, Liu Z-G, Ye J, Zhan Q, et al. 2006. IKKβ 
programs to turn on the GADD45α-MKK4-JNK apoptotic 
cascade specifically via p50 NF-κB in arsenite response. 
J Cell Biol 175(4):607–617.
Subbaramaiah K, Cole PA, Dannenberg AJ. 2002. Retinoids 
and carnosol suppress cyclooxygenase-2 transcription by 
CREB-binding protein/p300-dependent and -independent 
mechanisms. Cancer Res 62(9):2522–2530.
Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, et al. 
2001. Inhibition of JNK activation through NF-κB target 
genes. Nature 414(6861):313–317.
Wang Q, Wang X, Evers BM. 2003. Induction of cIAP-2 in 
human colon cancer cells through PKCδ/NF-κB. J Biol 
Chem 278(51):51091–51099.
Wang S, Chen F, Zhang Z, Jiang B, Jia L, Shi XL. 2004. NF-κB 
prevents cells from undergoing Cr(VI)-induced apoptosis. 
Mol Cell Biochem 255(1–2):129–137.
Wang YJ, Wang BJ, Sheu HM, Guo YL, Lee YH, Lai CS, et al. 
2010. Hexavalent chromium induced ROS formation, Akt, 
NF-κB, and MAPK activation, and TNF-α and IL-1α pro-
duction in keratinocytes. Toxicol Lett 198(2):216–224.
Wei YD, Tepperman K, Huang MY, Sartor MA, Puga A. 2004. 
Chromium inhibits transcription from polycyclic aromatic 
hydrocarbon-inducible promoters by blocking the release 
of histone deacetylase and preventing the binding of p300 
to chromatin. J Biol Chem 279:4110–4119.
Yao H, Guo L, Jiang BH, Luo J, Shi X. 2008. Oxidative stress and 
chromium(VI) carcinogenesis. J Environ Pathol Toxicol 
Oncol 27(2):77–88.
Zeidler-Erdely P, Kashon M, Battelli L, Young S-H, Erdely A, 
Roberts J, et al. 2008. Pulmonary inflammation and tumor 
induction in lung tumor susceptible A/J and resistant 
C57BL/6J mice exposed to welding fume. Part Fibre Toxicol 
5(1):12; doi:10.1186/1743-8977-5-12 [Online 8 September 
2008].
Zhang D, Li J, Song L, Ouyang W, Gao J, Huang C. 2008. A 
JNK1/AP-1-dependent, COX-2 induction is implicated in 
12-O-tetradecanoylphorbol-13-acetate-induced cell trans-
formation through regulating cell cycle progression. Mol 
Cancer Res 6(1):165–174.
Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ, Yang RF, et al. 
2010. SIRT1 suppresses activator protein-1 transcriptional 
activity and cyclooxygenase-2 expression in macrophages. 
J Biol Chem 285(10):7097–7110. 